BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yun W, Qian L, Yuan R, Xu H. Periplocymarin protects against myocardial fibrosis induced by β-adrenergic activation in mice. Biomed Pharmacother 2021;139:111562. [PMID: 33839492 DOI: 10.1016/j.biopha.2021.111562] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Boudoulas KD, Pitsis A, Triposkiadis F, Han Y, Savona SJ, Stefanadis C, Boudoulas H. Floppy mitral valve/mitral valve prolapse and sudden cardiac death. Progress in Cardiovascular Diseases 2022. [DOI: 10.1016/j.pcad.2022.10.010] [Reference Citation Analysis]
2 Fan CL, Liang S, Ye MN, Cai WJ, Chen M, Hou YL, Guo J, Dai Y. Periplocymarin alleviates pathological cardiac hypertrophy via inhibiting the JAK2/STAT3 signalling pathway. J Cell Mol Med 2022. [PMID: 35365949 DOI: 10.1111/jcmm.17267] [Reference Citation Analysis]
3 Syed AM, Kundu S, Ram C, Kulhari U, Kumar A, Mugale MN, Murty US, Sahu BD. Aloin alleviates pathological cardiac hypertrophy via modulation of the oxidative and fibrotic response. Life Sci 2022;288:120159. [PMID: 34801516 DOI: 10.1016/j.lfs.2021.120159] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Yun W, Qian L, Yuan R, Xu H. Periplocymarin Alleviates Doxorubicin-Induced Heart Failure and Excessive Accumulation of Ceramides. Front Cardiovasc Med 2021;8:732554. [PMID: 34869633 DOI: 10.3389/fcvm.2021.732554] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Wang S, Yu X, Wu S, Yang W, Gao Y, Wang W, Wang Q, Wei M, Zhu M, Wu J, Yuan Z, Li Y. Simultaneous determination of periplocin, periplocymarin, periplogenin, periplocoside M and periplocoside N of Cortex Periplocae in rat plasma and its application to a pharmacokinetic study. Biomed Chromatogr 2021;:e5283. [PMID: 34816469 DOI: 10.1002/bmc.5283] [Reference Citation Analysis]